Linaprazan glurate is under clinical development by Cinclus Pharma Holding and currently in Phase II for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase II drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linaprazan glurate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Linaprazan glurate overview

Linaprazan glurate (X-842) is under development for the treatment of gastroesophageal reflux disease, helicobacter pylori infection, gastric ulcer and duodenal ulcer. It is administered through oral route. It is a prodrug of linaprazan. The drug candidate belongs to potassium-competitive acid blocker (P-CAB). It acts by targeting hydrogen, potassium ATPase (H, K-ATPase).

Cinclus Pharma Holding overview

Cinclus Pharma Holding is a biotechnology company that develops small molecules for the treatment of gastric acid-related diseases. The company is headquartered in Stockholm City, Stockholm, Sweden.

For a complete picture of Linaprazan glurate’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.